Cann Group Past Earnings Performance

Past criteria checks 0/6

Cann Group's earnings have been declining at an average annual rate of -24.3%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 47.2% per year.

Key information

-24.3%

Earnings growth rate

0.3%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate47.2%
Return on equity-58.2%
Net Margin-137.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

Dec 27
A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

May 18
Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Nov 03
Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Feb 23
Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Nov 25
What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Nov 25
One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Revenue & Expenses Breakdown
Beta

How Cann Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:CAN Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2321-29352
30 Sep 2321-32353
30 Jun 2321-34344
31 Mar 2318-35284
31 Dec 2214-37275
30 Sep 2213-32274
30 Jun 2211-26283
31 Mar 2210-25272
31 Dec 219-24262
30 Sep 219-25252
30 Jun 219-25232
31 Mar 217-22192
31 Dec 206-18152
30 Sep 204-17142
30 Jun 202-17141
31 Mar 202-16151
31 Dec 193-14161
30 Sep 193-13151
30 Jun 193-11131
31 Mar 192-10111
31 Dec 181-891
30 Sep 181-671
30 Jun 181-561
31 Mar 180-441
31 Dec 170-320
30 Sep 170-321
30 Jun 170-321
30 Jun 160-110
30 Jun 150-440

Quality Earnings: CAN is currently unprofitable.

Growing Profit Margin: CAN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CAN is unprofitable, and losses have increased over the past 5 years at a rate of 24.3% per year.

Accelerating Growth: Unable to compare CAN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).


Return on Equity

High ROE: CAN has a negative Return on Equity (-58.21%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.